U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

MedGen UID:
925836
•Concept ID:
C4288304
•
Neoplastic Process
Synonyms: Recurrent Non-Squamous Non-Small Cell Lung Cancer; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma

Definition

The reemergence of non-squamous non-small cell lung carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Lung Non-Squamous Non-Small Cell Carcinoma

Professional guidelines

PubMed

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations.
Song R, Cheng Y, Zheng T
Contrast Media Mol Imaging 2022;2022:2228744. Epub 2022 Oct 11 doi: 10.1155/2022/2228744. PMID: 36304772Free PMC Article
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C
Lung Cancer 2009 Nov;66(2):141-9. Epub 2009 Jul 4 doi: 10.1016/j.lungcan.2009.06.006. PMID: 19577816
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F
Crit Rev Oncol Hematol 2008 Dec;68(3):183-96. Epub 2008 Jul 7 doi: 10.1016/j.critrevonc.2008.05.002. PMID: 18606548

Recent clinical studies

Etiology

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L).
Wakuda K, Kenmotsu H, Sato Y, Nakamura A, Akamatsu H, Tachihara M, Miura S, Yokoyama T, Mori K, Nakagawa K, Yamamoto N
BMC Cancer 2023 Sep 25;23(1):902. doi: 10.1186/s12885-023-11417-w. PMID: 37749521Free PMC Article
Carboplatin and weekly paclitaxel in combination with bevacizumab for the treatment of advanced non-small cell lung cancer complicated by idiopathic interstitial pneumonias: A feasibility study.
Omori M, Minegishi Y, Uruga H, Fukuizumi A, Isobe K, Izumi S, Koyama R, Bando M, Sugiyama H, Takahashi K, Gemma A, Homma S, Sugiyama Y, Kishi K
Respir Investig 2023 Sep;61(5):625-631. Epub 2023 Jul 11 doi: 10.1016/j.resinv.2023.06.002. PMID: 37441903
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M
Lancet Oncol 2019 May;20(5):625-635. Epub 2019 Apr 8 doi: 10.1016/S1470-2045(19)30035-X. PMID: 30975627
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K
Lung Cancer 2018 Aug;122:234-242. Epub 2018 May 24 doi: 10.1016/j.lungcan.2018.05.023. PMID: 30032838

Diagnosis

Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T, Sakai K, Kenmotsu H, Yoh K, Daga H, Ohira T, Ueno T, Aoki T, Hayashi H, Yamazaki K, Hosomi Y, Chen-Yoshikawa TF, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Inokawa H, Yamamoto N, Nishio K, Tsuboi M
Cancer Sci 2022 Jan;113(1):287-296. Epub 2021 Nov 7 doi: 10.1111/cas.15171. PMID: 34689382Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T, Udagawa H, Matsumoto S, Yoh K, Nosaki K, Ikeda T, Zenke Y, Kirita K, Niho S, Akimoto T, Goto K, Ishii G
J Cancer Res Clin Oncol 2021 Apr;147(4):1227-1237. Epub 2020 Sep 30 doi: 10.1007/s00432-020-03413-5. PMID: 32997195
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W, Franchini F, Alexander M, Officer A, Wong HL, IJzerman M, Desai J, Solomon BJ
Lung Cancer 2020 Aug;146:310-317. Epub 2020 Jun 26 doi: 10.1016/j.lungcan.2020.06.030. PMID: 32619782
Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
Morodomi Y, Takenoyama M, Inamasu E, Toyozawa R, Kojo M, Toyokawa G, Shiraishi Y, Takenaka T, Hirai F, Yamaguchi M, Taguchi K, Seto T, Sugio K, Ichinose Y
Anticancer Res 2014 Jul;34(7):3825-30. PMID: 24982409

Therapy

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M
J Immunother Cancer 2024 Feb 12;12(2) doi: 10.1136/jitc-2023-008189. PMID: 38346853Free PMC Article
MYL-1402O: A Bevacizumab Biosimilar.
Lee A
Target Oncol 2022 Jan;17(1):85-88. Epub 2021 Dec 15 doi: 10.1007/s11523-021-00858-7. PMID: 34910269Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M
Lancet Oncol 2019 May;20(5):625-635. Epub 2019 Apr 8 doi: 10.1016/S1470-2045(19)30035-X. PMID: 30975627
Bevacizumab in non-small cell lung cancer.
Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F
Drugs 2008;68(6):737-46. doi: 10.2165/00003495-200868060-00002. PMID: 18416583

Prognosis

Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T, Sakai K, Kenmotsu H, Yoh K, Daga H, Ohira T, Ueno T, Aoki T, Hayashi H, Yamazaki K, Hosomi Y, Chen-Yoshikawa TF, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Inokawa H, Yamamoto N, Nishio K, Tsuboi M
Cancer Sci 2022 Jan;113(1):287-296. Epub 2021 Nov 7 doi: 10.1111/cas.15171. PMID: 34689382Free PMC Article
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T, Udagawa H, Matsumoto S, Yoh K, Nosaki K, Ikeda T, Zenke Y, Kirita K, Niho S, Akimoto T, Goto K, Ishii G
J Cancer Res Clin Oncol 2021 Apr;147(4):1227-1237. Epub 2020 Sep 30 doi: 10.1007/s00432-020-03413-5. PMID: 32997195
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W, Franchini F, Alexander M, Officer A, Wong HL, IJzerman M, Desai J, Solomon BJ
Lung Cancer 2020 Aug;146:310-317. Epub 2020 Jun 26 doi: 10.1016/j.lungcan.2020.06.030. PMID: 32619782
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K
Lung Cancer 2018 Aug;122:234-242. Epub 2018 May 24 doi: 10.1016/j.lungcan.2018.05.023. PMID: 30032838
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C
Lung Cancer 2009 Nov;66(2):141-9. Epub 2009 Jul 4 doi: 10.1016/j.lungcan.2009.06.006. PMID: 19577816

Clinical prediction guides

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M
J Immunother Cancer 2024 Feb 12;12(2) doi: 10.1136/jitc-2023-008189. PMID: 38346853Free PMC Article
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T, Sakai K, Kenmotsu H, Yoh K, Daga H, Ohira T, Ueno T, Aoki T, Hayashi H, Yamazaki K, Hosomi Y, Chen-Yoshikawa TF, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Inokawa H, Yamamoto N, Nishio K, Tsuboi M
Cancer Sci 2022 Jan;113(1):287-296. Epub 2021 Nov 7 doi: 10.1111/cas.15171. PMID: 34689382Free PMC Article
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T, Udagawa H, Matsumoto S, Yoh K, Nosaki K, Ikeda T, Zenke Y, Kirita K, Niho S, Akimoto T, Goto K, Ishii G
J Cancer Res Clin Oncol 2021 Apr;147(4):1227-1237. Epub 2020 Sep 30 doi: 10.1007/s00432-020-03413-5. PMID: 32997195
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Cui W, Franchini F, Alexander M, Officer A, Wong HL, IJzerman M, Desai J, Solomon BJ
Lung Cancer 2020 Aug;146:310-317. Epub 2020 Jun 26 doi: 10.1016/j.lungcan.2020.06.030. PMID: 32619782
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C
Lung Cancer 2009 Nov;66(2):141-9. Epub 2009 Jul 4 doi: 10.1016/j.lungcan.2009.06.006. PMID: 19577816

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...